CD8+T-Cell-Mediated Cross-Clade Protection in the Genital Tract following Intranasal Immunization with Inactivated Human Immunodeficiency Virus Antigen Plus CpG Oligodeoxynucleotides
Open Access
- 1 January 2005
- journal article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 79 (1) , 393-400
- https://doi.org/10.1128/jvi.79.1.393-400.2005
Abstract
Human immunodeficiency virus (HIV) is a mucosally transmitted infection that rapidly targets and depletes CD4+ T cells in mucosal tissues and establishes a major reservoir for viral persistence in gut-associated lymphoid tissues. Therefore, vaccines designed to prevent HIV infections must induce potent and durable mucosal immune responses, especially in the genital tract. Here we investigated whether intranasal (i.n.) immunization with inactivated gp120-depleted HIV-1 antigen (Ag) plus CpG oligodeoxynucleotide (ODN) as an adjuvant induced local immune responses in the genital tract and cross-clade protection against intravaginal (IVAG) challenge. Lymphocytes isolated from the iliac lymph nodes (ILNs) and genital tracts of female mice i.n. immunized with HIV-1 Ag plus CpG showed significant HIV-specific proliferation and produced significantly higher levels of gamma interferon (IFN-γ) and β-chemokines than mice immunized with HIV-1 Ag alone or mixed with non-CpG ODN. CD8+ lymphocytes were dramatically increased in the genital tracts of mice immunized with HIV-1 Ag plus CpG, and protection following IVAG challenge with recombinant vaccinia viruses (rVVs) expressing HIV-1 gag was shown to be CD8 dependent. Finally, cross-clade protection was observed between clades A, C, and G but not B following IVAG challenge with rVVs expressing HIV-1 gag from different clades. These studies provide evidence that mucosal (i.n.) immunization induced strong local T-cell-mediated immune responses in the genital tract and cross-clade protection against IVAG challenge.Keywords
This publication has 44 references indexed in Scilit:
- Intravaginal immunization with viral subunit protein plus CpG oligodeoxynucleotides induces protective immunity against HSV-2Vaccine, 2004
- Potent Cross‐Group Neutralization of Primary Human Immunodeficiency Virus Isolates with Monoclonal Antibodies—Implications for Acquired Immunodeficiency Syndrome VaccineThe Journal of Infectious Diseases, 2004
- T Cell Dynamics in HIV-1 InfectionAnnual Review of Immunology, 2003
- Mucosal Immunization with Inactivated Human Immunodeficiency Virus plus CpG Oligodeoxynucleotides Induces Genital Immune Responses and Protection against Intravaginal ChallengeThe Journal of Infectious Diseases, 2002
- Creating space: an antigen-independent, CpG-induced peripheral expansion of naive and memory T lymphocytes in a full T-cell compartmentBlood, 2002
- CpG Motifs in Bacterial DNA and Their Immune EffectsAnnual Review of Immunology, 2002
- Control of a Mucosal Challenge and Prevention of AIDS by a Multiprotein DNA/MVA VaccineScience, 2001
- Immunostimulatory DNA Is a Potent Mucosal AdjuvantCellular Immunology, 1998
- HIV Type 1 Isolate Z321, the Strain Used to Make a Therapeutic HIV Type 1 Immunogen, Is Intersubtype RecombinantAIDS Research and Human Retroviruses, 1997
- Identification of RANTES, MIP-1α, and MIP-1β as the Major HIV-Suppressive Factors Produced by CD8 + T CellsScience, 1995